Evolution of the Average Target: Compass Therapeutics, Inc.

Evolution of the Target Price: Compass Therapeutics, Inc.

Changes in Analyst Recommendations: Compass Therapeutics, Inc.

55bac2a13fefcec521934a96ac7f0f38.v9qLxGR_8_eFEJICvVuGbik8BuN9mqY0qWw5T-d2BAw.04v6oT04ucKwV6Ns6DXqLVMJQtIt3_AH4i5OFbYgfWDggMS2XQumpedA0w~1932ecf29f9b5d7870658d4b5901ba45
04-28 Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform MT
04-27 Wedbush Lowers Compass Therapeutics Price Target to $5 From $8, Maintains Outperform Rating MT
01-05 William Blair Initiates Compass Therapeutics at Outperform MT
12-03 Canaccord Genuity Initiates Compass Therapeutics at Buy With $10 Price Target MT
12-03 Cantor Fitzgerald Initiates Compass Therapeutics at Overweight MT
02/04/25 Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 MT
24/02/25 Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target MT
19/02/25 Piper Sandler Initiates Compass Therapeutics at Overweight MT
16/09/24 Ladenburg Thalmann Upgrades Compass Therapeutics to Buy From Neutral MT
31/01/23 Jefferies Starts Compass Therapeutics at Buy With $8 Price Target MT
27/01/23 Stifel Initiates Compass Therapeutics at Buy With $9 Price Target MT
16/12/22 EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target MT
10/11/22 Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating MT
03/11/22 HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating MT
23/05/22 HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12 MT
05/05/22 SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating MT
15/03/22 Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target MT
19/01/22 B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround MT
22/12/21 Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target MT
20/12/21 SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target MT
15/12/21 Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target MT
19/11/21 Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+381.98%
+16.56%
+18.28%
+60.95%
+20.37%
+9.35%
+16.93%
-8.21%
+64.19%
+26.88%
Average +60.73%
Weighted average by Cap. +23.51%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.850USD
Average target price
8.917USD
Spread / Average Target
+381.98%
High Price Target
24.00USD
Spread / Highest target
+1,197.30%
Low Price Target
5.000USD
Spread / Lowest Target
+170.27%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. CMPX Stock
  4. Consensus Compass Therapeutics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!